{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:45:27Z","timestamp":1794617127914,"version":"4.9.1"},"reference-count":19,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0694-x","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T13:03:03Z","timestamp":1565010183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["A case of checkpoint inhibitor-induced celiac disease"],"prefix":"10.1136","volume":"7","author":[{"given":"Dana","family":"Alsaadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Charabaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-9924","authenticated-orcid":false,"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"issue":"2","key":"694_CR1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/1758834014567470","volume":"7","author":"R Sundar","year":"2015","unstructured":"Sundar R, Cho B, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85.","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"694_CR2","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. JCO. 2015;33(13):1430\u20137.","journal-title":"JCO."},{"issue":"5","key":"694_CR3","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","volume":"2","author":"DF McDermott","year":"2013","unstructured":"McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662\u201373.","journal-title":"Cancer Med"},{"issue":"1","key":"694_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.phrs.2011.09.002","volume":"65","author":"G Graziani","year":"2012","unstructured":"Graziani G, Tentori L, Navarra P. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacol Res. 2012;65(1):9\u201322.","journal-title":"Pharmacol Res"},{"issue":"4","key":"694_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.clon.2016.11.007","volume":"29","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O, Helbling D, Schmidt J, et al. Treatment-related death in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Clin Oncol. 2017;29(4):218.","journal-title":"Clin Oncol"},{"key":"694_CR6","unstructured":"US Department of Health and Human Services. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf . Accessed 24 Feb 2019."},{"issue":"8","key":"694_CR7","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"4","key":"694_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320\u201330.","journal-title":"N Engl J Med"},{"issue":"14","key":"694_CR9","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.3748\/wjg.v21.i14.4373","volume":"21","author":"P Rastogi","year":"2015","unstructured":"Rastogi P, Sultan M, Charabaty AJ, Atkins MB, Mattar MC. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital. World J Gastroenterol. 2015;21(14):4373\u20138.","journal-title":"World J Gastroenterol"},{"key":"694_CR10","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2018.17","volume":"5","author":"P Diana","year":"2018","unstructured":"Diana P, Mankongpaisarnrung C, Atkins MB, Zeck JC, Charabaty A. Emerging role of Vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis. ACG Case Rep J. 2018;5:e17. Published 2018 Feb 28. https:\/\/doi.org\/10.14309\/crj.2018.17 .","journal-title":"ACG Case Rep J"},{"issue":"4","key":"694_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/apt.13281","volume":"42","author":"A Gupta","year":"2015","unstructured":"Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42(4):406\u201317.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"694_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","volume":"4","author":"AN Shoushtari","year":"2017","unstructured":"Shoushtari AN, Friedman CF, Navid-Azarbaijani P, et al. Measuring toxic effects and time to treatment failure for Nivolumab plus Ipilimumab in melanoma. JAMA Oncol. 2017;4(1):98\u2013101.","journal-title":"JAMA Oncol"},{"issue":"5","key":"694_CR13","first-page":"560","volume":"4","author":"JAA Villadolid","year":"2015","unstructured":"Villadolid JAA. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Translational Lung Cancer Research. 2015;4(5):560.","journal-title":"Translational Lung Cancer Research"},{"key":"694_CR14","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.mayocp.2013.01.015","volume":"88","author":"NM Gentile","year":"2013","unstructured":"Gentile NM, D\u2019Souza A, Fujii LL, Wu TT, Murray JA. Association between ipilimumab and celiac disease. Mayo Clin Proc. 2013;88:414\u20137.","journal-title":"Mayo Clin Proc"},{"key":"694_CR15","first-page":"297","volume":"4","author":"SA Scanlon","year":"2011","unstructured":"Scanlon SA, Murray JA. Update on celiac disease\u2014etiology, differential diagnosis, drug targets, and management advances. Clin Exp Gastroenterol. 2011;4:297\u2013311.","journal-title":"Clin Exp Gastroenterol"},{"issue":"1","key":"694_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.gtc.2018.09.003","volume":"48","author":"SM Lagana","year":"2019","unstructured":"Lagana SM, Bhagat G. Biopsy diagnosis of celiac disease. The Pathologist's Perspective in Light of Recent Advances Gastroenterol Clin North Am. 2019;48(1):39\u201351.","journal-title":"The Pathologist's Perspective in Light of Recent Advances Gastroenterol Clin North Am"},{"key":"694_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/857519","volume":"2013","author":"A Tarhini","year":"2013","unstructured":"Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica. 2013;2013:857519.","journal-title":"Scientifica."},{"key":"694_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000278","volume":"3","author":"MH Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.","journal-title":"ESMO Open"},{"issue":"8","key":"694_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/ibd\/izy104","volume":"24","author":"Yinghong Wang","year":"2018","unstructured":"Wang Y, Abu-Sbeih H, Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24(8).","journal-title":"Inflammatory Bowel Diseases"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0694-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0694-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T02:12:04Z","timestamp":1610763124000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0694-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0694-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"15 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This case report was exempt from the local ethical committee. Written informed consent was obtained from the patient for treatment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"203"}}